The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Organon & Co. (NYSE:OGN) is one of the 10 Stocks Powering Portfolios by Double Digits.

Organon surged by 38.8 percent week-on-week, as investors gobbled up shares following reports that it is set to be acquired by Sun Pharmaceutical Industries for $12 billion.

According to a report by India-based The Economic Times, Sun Pharmaceutical submitted an offer to fully acquire Organon & Co. (NYSE:OGN) in an all-cash transaction. The two firms have yet to confirm or deny the reports.

Photo by Pietro Jeng on Pexels

Organon & Co. (NYSE:OGN) was spun off from Merck in 2021. It is engaged in the development of therapies for reproductive health, women’s health, and contraception, among others.

Earlier this year, the listed US-based firm announced results from the late-stage clinical trial of its VTAMA cream—the only aryl hydrocarbon receptor (AhR) agonist indicated for the treatment of both plaque psoriasis in adults, as well as atopic dermatitis (AD) in adults and pediatric patients aged 2 years and above.

Based on the results, the treatment candidate demonstrated early and consistent improvement in disease severity, as measured by vIGA-AD and EASI, and itch, as measured by PP-NRS, for patients down to age 2 with moderate to severe AD.

In other news, Organon & Co. (NYSE:OGN) posted a dismal earnings performance last year, with net income plunging by 78 percent to $187 million from $864 million in 2024. Revenues also dipped by 3 percent to $6.2 billion from $6.4 billion year-on-year.

In the fourth quarter alone, the company swung to a net loss of $205 million from a $109 million net income in the same quarter a year earlier, while revenues decreased by 5.3 percent to $1.5 billion from $1.59 billion year-on-year.

While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.